Join
Live feed
·
PRReleasevia Quantisnow
Affimed N.V. logo

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

ByQuantisnow·Wall Street's wire, on your screen.
AFMD· Affimed N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AFMD (Affimed N.V.) and more on Quantisnow.